Maria João Meneses

Ms. Maria João Meneses

NOVA Medical School | Faculdade de Ciências Médicas, Lisbon, Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Maria João MenesesMaria João Meneses
Maria João Meneses
RSRegina Silvestre
Regina Silvestre
ILINES SOUSA LIMA
INES SOUSA LIMA
MMMaria Paula Macedo
Maria Paula Macedo
Metabolic disorders are characterized by an overall state of inflammation and oxidative stress, which highlight the importance of a functional antioxidant system and normal activity of some endogenous enzymes, namely paraoxonase-1 (PON1). PON1 is an antioxidant and anti-inflammatory glycoprotein from the paraoxonases family. It is mainly expressed in the liver and secreted to the bloodstream, where it binds to HDL. Although it was first discovered due to its ability to hydrolyze paraoxon, it is now known to have an antiatherogenic role. Recent studies have shown that PON1 plays a protective role in other diseases that are associated with inflammation and oxidative stress, such as Type 1 and Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease. The aim of this review is to elucidate the physiological role of PON1, as well as the impact of altered PON1 levels in metabolic disorders.

18 August 2015 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
Maria João MenesesMaria João Meneses
Maria João Meneses
BSBranca Silva
Branca Silva
MSMário Sousa
Mário Sousa
RSRosália Sá
Rosália Sá
Pedro F. OliveiraPedro F. Oliveira
Pedro F. Oliveira
Marco AlvesMarco Alves
Marco Alves
Diabetes mellitus (DM) is one of the most prevalent chronic diseases and has been a leading cause of death in the last decades. Thus, methods to detect, prevent or delay this disease and its co-morbidities have long been a matter of discussion. Nowadays, DM patients, particularly those suffering with type 2 DM, are advised to alter their diet and physical exercise regimens and then proceed progressively from monotherapy, dual therapy, and multi-agent therapy to insulin administration, as the disease becomes more severe. Although progresses have been made, the pursuit for the “perfect” antidiabetic drug still continues. The complexity of DM and its impact on whole body homeodynamics are two of the main reasons why there is not yet such a drug. Moreover, the molecular mechanisms by which DM can be controlled are still under an intense debate. As the associated risks, disadvantages, side effects and mechanisms of action vary from drug to drug, the choice of the most suitable therapy needs to be thoroughly investigated. Herein we propose to discuss the different classes of antidiabetic drugs available, their applications and mechanisms of action, particularly those of the newer and/or most widely prescribed classes. A special emphasis will be made on their effects on cellular metabolism, since these drugs affect those pathways in several cellular systems and organs, promoting metabolic alterations responsible for either deleterious or beneficial effects. This is a crucial property that needs to be carefully investigated when prescribing an antidiabetic.

16 August 2021 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
LSLuís Sousa
Luís Sousa
MGMariana Guarda
Mariana Guarda
Maria João MenesesMaria João Meneses
Maria João Meneses
MMMaria Paula Macedo
Maria Paula Macedo
Hugo Vicente MirandaHugo Vicente Miranda
Hugo Vicente Miranda

1 October 2016 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
Maria João MenesesMaria João Meneses
Maria João Meneses
RBRaquel L. Bernardino
Raquel L. Bernardino
RSR. Sá
R. Sá
JSJ. Silva
J. Silva
ABA. Barros
A. Barros
Marco AlvesMarco Alves
Marco Alves

5 November 2022 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
APAna Pina
Ana Pina
Maria João MenesesMaria João Meneses
Maria João Meneses
ILINES SOUSA LIMA
INES SOUSA LIMA
Roberto HenriquesRoberto Henriques
Roberto Henriques
JRJOÃO FILIPE RAPOSO
JOÃO FILIPE RAPOSO
MMMaria Paula Macedo
Maria Paula Macedo
Background: Type 2 Diabetes (T2D) diagnosis is based solely on glycaemia, even though it is an endpoint of numerous dysmetabolic pathways. Type 2 Diabetes complexity is challenging in a real‐world scenario; thus, dissecting T2D heterogeneity is a priority. Cluster analysis, which identifies natural clusters within multidimensional data based on similarity measures, poses a promising tool to unravel Diabetes complexity.Methods: In this review, we scrutinize and integrate the results obtained in most of the works up to date on cluster analysis and T2D.Results: To correctly stratify subjects and to differentiate and individualize a preventive or therapeutic approach to Diabetes management, cluster analysis should be informed with more parameters than the traditional ones, such as etiological factors, pathophysiological mechanisms, other dysmetabolic co‐morbidities, and biochemical factors, that is the millieu. Ultimately, the above‐mentioned factors may impact on Diabetes and its complications. Lastly, we propose another theoretical model, which we named the Integrative Model. We differentiate three types of components: etiological factors, mechanisms and millieu. Each component encompasses several factors to be projected in separate 2D planes allowing an holistic interpretation of the individual pathology.Conclusion: Fully profiling the individuals, considering genomic and environmental factors, and exposure time, will allow the drive to precision medicine and prevention of complications.

20 December 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
Margarida CoelhoMargarida Coelho
Margarida Coelho
RPRita Patarrão
Rita Patarrão
ILINES SOUSA LIMA
INES SOUSA LIMA
RRRogério T. Ribeiro
Rogério T. Ribeiro
Maria João MenesesMaria João Meneses
Maria João Meneses
John JonesJohn Jones
John Jones
Coffee may protect against non-alcoholic fatty liver disease (NAFLD), but the roles of the caffeine and non-caffeine components are unclear. Coffee intake by 156 overweight subjects (87% with Type-2-Diabetes, T2D) was assessed via a questionnaire, with 98 subjects (all T2D) also providing a 24 h urine sample for quantification of coffee metabolites by LC–MS/MS. NAFLD was characterized by the fatty liver index (FLI) and by Fibroscan® assessment of fibrosis. No associations were found between self-reported coffee intake and NAFLD parameters; however, total urine caffeine metabolites, defined as Σcaffeine (caffeine + paraxanthine + theophylline), and adjusted for fat-free body mass, were significantly higher for subjects with no liver fibrosis than for those with fibrosis. Total non-caffeine metabolites, defined as Σncm (trigonelline + caffeic acid + p-coumaric acid), showed a significant negative association with the FLI. Multiple regression analyses for overweight/obese T2D subjects (n = 89) showed that both Σcaffeine and Σncm were negatively associated with the FLI, after adjusting for age, sex, HbA1c, ethanol intake and glomerular filtration rate. The theophylline fraction of Σcaffeine was significantly increased with both fibrosis and the FLI, possibly reflecting elevated CYP2E1 activity—a hallmark of NAFLD worsening. Thus, for overweight/obese T2D patients, higher intake of both caffeine and non-caffeine coffee components is associated with less severe NAFLD. Caffeine metabolites represent novel markers of NAFLD progression.